ClinicalTrials.gov
ClinicalTrials.gov Menu

Zambia Micronutrient Powder Trial Effectiveness Study

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT01878734
Recruitment Status : Completed
First Posted : June 17, 2013
Last Update Posted : June 4, 2015
Sponsor:
Collaborators:
Tropical Disease Research Centre
UNICEF
Ministry of Health, Zambia
Information provided by (Responsible Party):
University of British Columbia

Brief Summary:
Addressing micronutrient deficiencies in Zambia is recognized as a national priority by the government due to its major contribution to morbidity and mortality among children, especially infants in their formative years. One of the most successful, cost-effective, and recommended strategy to address micronutrient malnutrition is 'in-home fortification' with micronutrient powders (Sprinkles being the most widely recognized) along with nutrition education. While this intervention has proven to be safe, effective, and efficacious in numerous other countries, a specific national protocol must be developed to maximize its effect on reducing anaemia in Zambian children. The proposed research aims to inform such protocol.

Condition or disease Intervention/treatment Phase
Iron Deficiency Anaemia Stunting Dietary Supplement: Micronutrient Powders Not Applicable

  Hide Detailed Description

Detailed Description:
  1. Purpose While Zambia has made progress towards reducing under-nutrition among children, as measured by underweight, other indicators of nutritional status, particularly stunting and anaemia have remained unchanged over the past decades. Repeated national surveys show that anaemia remains of public health significance among Zambian children. According to WHO classification, a prevalence of anaemia above 40% is categorized as a severe public health problem. There has been no significant reduction in anaemia among children 6-59 months over the past two decades with an estimated prevalence of 60% in 1998, 53% in 20032 and 49% in 20093. Further, younger infants were found to be more affected than older children with an estimated prevalence of 81% in children 6-18 months in 1992 and 61% in children 6-24 months in 2009. In developing countries approximately 50% of all anaemia is attributed to iron deficiency. It is further estimated that the frequency of iron deficiency is about 2.5 times that of anaemia, and when anaemia prevalence exceeds 40%, it is assumed that the entire population is suffering from some degree of iron deficiency. It is therefore assumed that this is the case with young children in Zambia. It is well established that iron deficiency has adverse health consequences even before anaemia develops. These include cognitive impairment, decreased physical capacity and reduced immunity.

    The most promising strategy for this age group is 'home fortification' of staple complementary foods (foods that are consumed in addition to breast milk after 6 months of age) with small packets of Micronutrient Powders (MNP) that can be easily mixed with home-prepared food.

    MNP are packed in single-serve sachets of mixed vitamins and minerals in powder form, which can be instantly sprinkled on prepared ready-to-eat complementary foods for young children without changing the colour or taste of the food. The sachets are packed to ensure that the correct amounts of micronutrients are given.

    As 'stunting', low height for age, is a problem of public health significance in Zambia with 45% of children under five being stunted, this programme will specifically address practices that will help to improve nutritional intake and reduce infection in order to promote growth during the early years of life.

    Therefore the purpose of this project will be to conduct a 12 month trial of MNP in the Northern Province of Zambia, in order to inform a future scale up.

  2. Justification Home fortification with MNP has proved to be efficacious and effective in reducing the prevalence of iron deficiency anaemia in young children. Today, MNP are successfully used in 45-50 countries worldwide. Based on the large body of evidence available, the WHO strongly recommends the use of MNP containing at least iron, vitamin A and zinc to improve iron status and reduce anaemia in children 6-23 months of age where the prevalence of anaemia in children under two years or under five years of age is 20% or higher.

    Previous trials have shown a reduction in anaemia by 31%, iron deficiency by 51% in young children consuming MNP and by 20-30% in a few programmatic settings. Furthermore, MNP have been shown to be as effective in treating and preventing anaemia as iron syrup. In 2011, studies in both Nepal and Kenya reported a significant decrease in the prevalence of stunting following the inclusion of MNP in programmes for children 6-59 months of age.

    While studies have demonstrated MNP to be efficacious and effective in specific settings, it is recognized that the findings from one country are not transferable to another due to differences in acceptability in accordance with cultural practices, economics, food availability and particularly infant and child feeding practices. This project was designed to fill the need for a country specific programme with regionally relevant training materials, packaging, messages for mothers and distribution system.

    Through our previous work we developed communications materials and packaging for MNP in Zambia following a feasibility study and 30-day trial. We evaluated acceptability, utilization and compliance of MNP and have modified training materials based on our findings. We are now prepared to conduct a 12-month pilot study on MNP integrated with IYCF in two districts as the basis for developing an evidence-based policy for implementing MNP at scale in Zambia.

  3. Objectives of the MNP Pilot

    • To demonstrate effectiveness of MNP in reducing iron deficiency and anaemia in children 6-23 months after 12 months of supplementation;
    • To evaluate the effectiveness of an integrated MNP and IYCF package in improving child nutritional status and growth;
    • To quantify the impact of an integrated MNP and IYCF package on reducing iron deficiency and anaemia and improving the nutritional status of children.
    • To develop a MNP communication strategy and Behaviour Change Communication materials.
    • To develop a national plan and policy recommendations for the scale-up and integration of MNP into IYCF.
  4. Research Method The 'Home Fortification Programme with MNP for Young Children in Zambia' has been designed as a multiphase project with the first phase consisted of two components, a feasibility study and a 30-day trial of MNP. The findings of the previously conducted feasibility study and the 30-day trial have been integrated into the design of the pilot phase, which will inform how best to scale up the MNP intervention in Zambia.

Methods have been developed in accordance with the overall pilot programme goals and objectives, taking into consideration the limitations of implementing a rigorous scientific design in resource poor settings where access, transportation and communication, are limited. Ethical considerations do not allow for a control group as the prevalence of anaemia is presumed to be high and the efficacy of MNP at reducing anaemia, established.

The pilot will be conducted in rural communities of Mbala district in the Northern Province.

The population for the government's MNP and IYCF intervention is all children 6-23 months and their caregivers, living in Mbala district, Northern Province. It is estimated that due to logistical constraints, of 26 health facilities, only 9 will be involved in the pilot. Therefore the target population will be approximately 2,350 children.

The formulation for the MNP used in the pilot will contain 15 micronutrients including iron, zinc, vitamin A, C, D, B group vitamins, folic acid and iodine in order to control other micronutrient deficiencies commonly found in the same individuals. The formulation takes into account the recommended daily micronutrient requirements for children 6-23 months, the availability from other sources including on-going nutrition programmes and the upper level of individual micronutrients. The MNP formula can be safely provided to children that receive bi-annual high dose vitamin A, or consume iodized salt.

Caregivers of children 6-23 months will be supplied with boxes of 30 sachets every two months over the duration of one year. This will cover 50% of the recommended Nutrient Intake for iron for a child in this age group. The MNP will be delivered to selected families through the primary health care system.

An effectiveness study has been embedded within the pilot programme to assess the effect of the MNP plus IYCF intervention package in relation to the programme's goals and outcomes under programmatic conditions within the target population. There will be two distinct groups invited to participate in the effectiveness component of the pilot, both in the district of Mbala. One will serve as a control group, and as such will not receive MNP. Both the treatment group and control groups will receive IYCF and early child development (ECD) training, deworming tablets (Mebendazole) and insecticide-treated nets, while the treatment group will additionally receive MNP.

Mother-child pairs from the two groups will be closely followed across the 12 month intervention period with an in-depth assessment taking place at three points in time; baseline, 6 months and 12 months after the intervention begins. The baseline evaluation will be conducted before the mothers are trained in the use of MNP as part of complementary feeding. The tools used for the assessment are described below.

The primary outcome variable used for the determination of the sample size for the effectiveness component of the study is a change in prevalence of anaemia among participating children (defined as haemoglobin < 11.0 g/dL) over the course of the 12-month intervention in the district of Mbala

Data collected will include anthropometry, in the form of MUAC, wasting (Weight-for-height), stunting (height-for-age), and weight-for-age. Biochemical data will be haemoglobin, serum ferritin, and serum transferrin receptor to measure iron status, C-reactive protein and alpha-1 acid glycoprotein will be used to control for infections, and retinol binding protein to measure vitamin A status. There will also be questionnaires, consisting of quantitative and qualitative questions, that will be administered.

6) Statistical Analysis

Data will be entered in the field into Excel and later transferred to an SPSS file for analysis. At baseline, descriptive characteristics will be calculated for all variables and key outcome variables compared across groups. At midline and end-line comparisons will be made across time among the three groups using means, standard deviation, and proportions as relevant. The p-value will be set at 0.05 with adjustments made for multiple comparisons.


Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 631 participants
Allocation: Non-Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)
Primary Purpose: Prevention
Official Title: MNP Pilot Study for Development of a Micronutrient Powder Home Fortification Program to Combat Anaemia Among Children 6-23 Months in Zambia
Study Start Date : June 2013
Actual Primary Completion Date : November 2014
Actual Study Completion Date : November 2014

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Anemia Iron
U.S. FDA Resources

Arm Intervention/treatment
No Intervention: Control
This arm will act as a control and will not receive Micronutrient Powders
Experimental: Micronutrient Powders
This is the treatment arm, which will be receiving Micronutrient Powders (MNP)
Dietary Supplement: Micronutrient Powders
Mothers will receive a one box containing 30 sachets of Micronutrient Powders (MNP) every other month. MNP will be procured offshore with support from UNICEF Supply Division in Copenhagen, which maintains a list of approved MNP suppliers and ensures compliance with standard requirements and product specifications. For this study MNP will be purchased from Piramal Healthcare Ltd, India.



Primary Outcome Measures :
  1. Change from Baseline in the occurrence of Iron Deficiency Anemia [ Time Frame: One year ]

Secondary Outcome Measures :
  1. Change from Baseline in the Occurrence of Stunting [ Time Frame: One year ]


Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   6 Months to 11 Months   (Child)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   Yes
Criteria

Inclusion Criteria:

  • Aged 6-11
  • Residing within the project catchment area, and plan on remaining in the same household for the 12 month study duration
  • Parent/guardian willingness to give consent for the child's participation in the study

Exclusion Criteria:

  • Weight-for-height Z score <3 SD
  • Mid-upper arm circumference < 11.5 cm
  • Presence of bilateral oedema
  • Severe anaemia (Hb < 7.0 g/dl)
  • HIV positive

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01878734


Locations
Zambia
Villages in the Mbala District
Mbala, Northern Province, Zambia
Sponsors and Collaborators
University of British Columbia
Tropical Disease Research Centre
UNICEF
Ministry of Health, Zambia
Investigators
Principal Investigator: Mélanie Suter University of British Columbia
Principal Investigator: Agnes Aongola Ministry of Health, Zambia

Responsible Party: University of British Columbia
ClinicalTrials.gov Identifier: NCT01878734     History of Changes
Other Study ID Numbers: H13-00261
First Posted: June 17, 2013    Key Record Dates
Last Update Posted: June 4, 2015
Last Verified: June 2015

Additional relevant MeSH terms:
Anemia
Anemia, Iron-Deficiency
Hematologic Diseases
Anemia, Hypochromic
Iron Metabolism Disorders
Metabolic Diseases
Micronutrients
Trace Elements
Growth Substances
Physiological Effects of Drugs